Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Newsom Eye is Leading the Way in the Treatment of Keratoconus with Epi-On Corneal Collagen Cross-Linking
  • USA - English


News provided by

Denali Creative- A Stubenbordt Company

Apr 27, 2017, 03:00 ET

Share this article

Share toX

Share this article

Share toX

T. Hunter Newsom, MD, Founder and Medical Director of Newsom Eye
T. Hunter Newsom, MD, Founder and Medical Director of Newsom Eye

Tampa, FL (PRWEB) April 27, 2017 -- For patients diagnosed with keratoconus, a new treatment option is now available in Tampa. Newsom Eye, with locations in Sebring and Tampa, is excited to announce that it is now offering Epi-On Corneal Collagen Cross-Linking (CXL, C3-R, CCL) for treating keratoconus. Newsom Eye is able to offer this new treatment by being a part of investigational research with FDA Institutional Review Boards (IRB) with ophthalmologists throughout the East Coast to advance this important research and reach FDA approval.

Newsom Eye is excited to reduce the amount of cornea transplants needed by offering Corneal Collagen Cross-Linking (CXL) to treat keratoconus.

Post this

Keratoconus is an eye disease that causes the cornea to become thin over time, and in some patients, the disease can cause the cornea to bulge or become cone shaped. Corneal Collagen Cross-Linking (CXL) has been proven to slow or even stop the progression of keratoconus. At Newsom Eye, the doctors offer a newer form of cross-linking called Epi-On. This new procedure allows for a much faster recover time with less discomfort over traditional cross-linking procedures that remove the epithelial layer. In addition, the cross-linking procedure performed at Newsom Eye typically takes five minutes versus 30 minutes as with other methods of performing the procedure.

The CXL Procedure

The collagen cross-linking treatment is an outpatient procedure performed in the doctor’s office. First, patients will be given anesthetic (numbing) eye drops to prevent pain or discomfort. Specially formulated vitamin B2 (riboflavin) eye drops are then instilled in the eye. The doctor will check your eye to make sure that the riboflavin drops have saturated the cornea so that the treatment will be effective. Next, the patient will relax in a reclining chair and look up at a soft blue ultraviolet light during the treatment. This light "activates" the riboflavin, which causes the cross-linking of the collagen fibers to occur.

Cross-Linking Effectiveness

In the past, in addition to wearing hard contacts, many patients with progressive keratoconus had to undergo a cornea transplant. However, clinical studies have shown that the majority of patients treated with Collagen Cross-Linking (CXL) have the progression of keratoconus slowed or even stopped. More than half of these patients had improved vision following the treatment.

The earlier the disease is treated, the better the results. If cross-linking is performed early it may be possible to prevent the signs and symptoms of keratoconus in some eyes with "pre-clinical" keratoconus.

T. Hunter Newsom, MD, Founder and Medical Director of Newsom Eye said, “Newsom Eye is excited to reduce the amount of cornea transplants needed by offering Corneal Collagen Cross-Linking (CXL) to treat keratoconus. In addition, offering Epi-On CXL in a fast five minute procedure allows us to improve patient comfort and provide a faster visual recovery.”

Collagen Cross-Linking Benefits

  • Slows or Halts Progressive Keratoconus
  • Typically Requires Only a Single Treatment
  • No Injections or Stitches Required
  • Fast Recovery

For more information about Epi-On Corneal Collagen Cross-Linking (CXL) at Newsom Eye, please call 813-867-4500 and ask to speak to our CXL Coordinator or visit NewsomEye.com.

About Newsom Eye

Founded by T. Hunter Newsom, MD, Newsom Eye is one of the leading multispecialty eye-care practices in central and west Florida, providing patients with NEWsom EYES!

Newsom Eye’s mission is to deliver top quality physicians and surgeons, supported by the most advanced research facilities and technology, while emphasizing customer care. Newsom Eye offers comprehensive eye care, including routine eye exams, Newsom Custom LASIK, laser cataract surgery, treatment of the cornea and retina, glaucoma treatment, as well as optical and audiology services.

All surgeries are performed in ambulatory surgery centers. These ambulatory surgery centers hold Medicare-deemed status through accreditation by the Accreditation Association for Ambulatory Health Care (AAAHC), which is the highest level of nationally recognized standard of care for outpatient surgery centers.

Newsom Eye has received numerous accolades, including “Best Eye Surgeon” by Tampa Tribune’s “Best of the Bay” and Sebring’s Highlands Today’s “People’s Choice” awarded Newsom Eye with “Best Eye Surgeon” and “Best Eye Clinic.”

To schedule an appointment, call (813) 908-2020 or schedule online at NewsomEye.com.

Megan Montefusco, Denali Creative- A Stubenbordt Company, http://stubenbordt.com, +1 682-831-0900 Ext: 105, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.